<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id>
      <journal-title-group>
        <journal-title>BMC Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2377</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27089920</article-id>
      <article-id pub-id-type="pmc">4835842</article-id>
      <article-id pub-id-type="publisher-id">572</article-id>
      <article-id pub-id-type="doi">10.1186/s12883-016-0572-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reversible splenial lesion syndrome associated with encephalitis/encephalopathy presenting with great clinical heterogeneity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>Yuanzhao</given-names>
          </name>
          <address>
            <email>846366855@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Junjun</given-names>
          </name>
          <address>
            <email>zjj259@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Ling</given-names>
          </name>
          <address>
            <email>601944681@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zeng</surname>
            <given-names>Zhenguo</given-names>
          </name>
          <address>
            <email>zzg6501@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>Min</given-names>
          </name>
          <address>
            <email>zhumin1@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Xiaobin</given-names>
          </name>
          <address>
            <email>lxb0203208@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lou</surname>
            <given-names>Xiaoliang</given-names>
          </name>
          <address>
            <email>895936295@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wan</surname>
            <given-names>Hui</given-names>
          </name>
          <address>
            <email>ncwanhui@sina.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hong</surname>
            <given-names>Daojun</given-names>
          </name>
          <address>
            <phone>86-791-8869-2511</phone>
            <email>hongdaojun@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Neurology, the First Affiliated Hospital of Nanchang University, Yong Wai Zheng Street 17#, Nanchang, 330006 P. R. China </aff>
        <aff id="Aff2"><label/>Department of Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China </aff>
        <aff id="Aff3"><label/>Department of Neurology, the Fourth Affiliated Hospital of Nanchang University, Nanchang, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>16</volume>
      <elocation-id>49</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Zhu et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Reversible splenial lesion syndrome (RESLES) is a disorder radiologically characterized by reversible lesion in the splenium of the corpus callosum (SCC). Most of patients with RESLES associated with encephalitis/encephalopathy were identified in Japanese population, but almost no Chinese patients were diagnosed as RESLES associated with encephalitis/encephalopathy.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Possible patients with reversible isolated SCC lesions were retrieved from January 2012 to July 2015 using keyword &#x201C;restricted diffusion and isolated SCC lesion&#x201D; in MRI report system from a large academic center. The clinical, laboratory and radiological data were summarized.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A total of 15 encephalitis/encephalopathy patients (9 males and 6 females) were identified with a reversible isolated SCC lesion. Except for 13 patients with fever symptom, 8 patients also had cold symptoms before the onset of neurological symptoms. The neurological symptoms included headache, vertigo, seizure, disturbance of consciousness, and delirious behavior. Thirteen patients completely recovered within 1&#xA0;month, but 2 patients who were subjected to mechanical ventilation had persistent neurological deficits. The initial MRI features showed isolated ovoid or extending SCC lesions with homogeneous hyperintense on diffusion weighted imaging (DWI) and decreased apparent diffusion coefficient (ADC) values. The follow-up MRI revealed that isolated SCC lesions with diffuse restriction disappeared at 10 to 32&#xA0;days after the initial MRI study. Fractional anisotropy map revealed the decreased value of SCC lesion in a severe case with poor prognosis.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>RESLES associated with encephalitis/encephalopathy is a reversible syndrome with an excellent prognosis in most patients, while a few patients required ventilator supporting at the early stage might have severe neurological sequelae. Reversible signal changes on DWI and ADC are identified in all patients, but fractional anisotropy values can be decreased in severe patient with neurological sequelae.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/s12883-016-0572-9) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Reversible splenial lesion syndrome</kwd>
        <kwd>Encephalitis</kwd>
        <kwd>Encephalopathy</kwd>
        <kwd>Corpus callosum</kwd>
        <kwd>Poor outcome</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
              <institution>National Natural Science Foundation of China (CN)</institution>
            </institution-wrap>
          </funding-source>
          <award-id>No.81260194 and 81460199</award-id>
          <principal-award-recipient>
            <name>
              <surname>Hong</surname>
              <given-names>Daojun</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Reversible splenial lesion syndrome (RESLES) is characterized by reversible lesion in the central portion of the splenium of corpus callosum (SCC) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. RESLES is most often identified in patients with seizures and/or antiepileptic drugs withdrawal [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, it is also frequently observed in encephalitis/encephalopathy caused by various pathogens such as influenza virus, rotavirus, measles, herpesvirus 6, adenovirus, mumps, Epstein-Barr virus, <italic>Escherischia coli</italic>, and others [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. The neurological symptoms of RESLES associated with encephalitis/encephalopathy can presented with delirious behavior, short disturbance of consciousness, and seizures, but usually had complete recovery without neurological sequelae after a short disease course [<xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. Therefore at sometimes, RESLES associated with encephalitis/encephalopathy was interchangeably termed as clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>Most of patients with RESLES associated with encephalitis/encephalopathy were reported in Japanese population [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. However, there were few published reports of Chinese patients diagnosed as RESLES associated with encephalitis/encephalopathy. In this study, we described the clinical data and outcomes in 15 Chinese patients with RESLES associated with encephalitis/encephalopathy identified retrospectively in order to evaluate the clinical heterogeneity of RESLES associated with encephalitis/encephalopathy.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <p>We performed a retrospective observational study in an academic hospital. Patients with isolated lesion in the splenium of corpus callosum visited in the first affiliated hospital of Nanchang University between January 2012 and July 2015 were screened for the study. We identified all patients by searching our MRI report system using keyword &#x201C;restricted diffusion and isolated SCC lesion&#x201D;. Exclusion criteria include epilepsy-related RESLES, RESLES with additional lesions in white matter, and cases without follow-up MRI. We reviewed and analyzed MRI scans and clinical charts of these patients, including information about symptoms, treatments, prognosis, electroencephalogram (EEG), and results of cerebrospinal fluid (CSF) analysis. The clinical data and radiological examinations were independently evaluated by at least two neurologists firstly. A reversible isolated SCC lesion is defined as a lesion involving the central portion of SCC without any other lesions on the first MRI, which disappears on the follow-up scanning. According to the literatures and clinician consensus, the diagnosis of encephalitis had been defined as acute onset of brain dysfunction such as acute fever, headache, seizures, delirious behavior, and disorders of consciousness with inflammatory changes such as pleocytosis of CSF [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. When patients presented with prodromal febrile illness, but without evidence of inflammatory change in central nervous system, we used the term encephalopathy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Fever is defined as mouth temperature more than 38&#xA0;&#xB0;C within the 72&#xA0;h before or after presentation. The clinical procedure of etiology investigating for encephalitis includes blood, CSF, and urine cultures; CSF gram stain, India Ink stain, and modified acid-fast stain; CSF polymerase chain reaction (PCR) for herpes simplex virus 1 or 2, Epstein-Barr virus, and influenza A or B; PCR for influenza A or B in nasopharyngeal swabs; herpes simplex virus 1 (HSV1), HSV2, HSV6, cytomegalovirus, Epstein-Barr virus, and varicella-zoster virus serum IgM, and 14 d later for paired IgG antibody testing; routine human immuno-deficiency virus, treponema pallidum agglutination test, and venereal disease research laboratory test.</p>
      <p>This study was approved by the ethics committee of the First Affiliated Hospital of Nanchang University. The written consent forms for clinical descriptions and radiological images were signed by the patients or their guardians. Herein, two cases with poor outcomes were singled out and described in detail as follows, and other patients&#x2019; descriptions were deposited in an Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p>
      <sec id="Sec3">
        <title>Case 2</title>
        <p>A 23-year-old man with the complaints of fever for 6&#xA0;days, disturbance of consciousness for 4&#xA0;h was admitted to the hospital on March 14, 2012. The patient initially presented with cold symptoms including fever, nasal congestion, and pharyngalgia 6&#xA0;days ago. At the day of admission, he had temperature up to 39&#xA0;&#xB0;C, severe headache, and vomiting. He suddenly lost consciousness and experienced a seizure at that night. The symptom of seizure completely stopped after 2&#x2013;3&#xA0;min, but coma was persistent. Physical examination on admission revealed comatose state (Glasgow Coma Scale, GCS: 7), cyanosis, stiff neck, and no voluntary movements. The emergent therapy included mechanical ventilation, antiviral (acyclovir), and antibiotics (cefoperazone). At 1&#xA0;day after admission, he can detach from the ventilator, but still was in comatose state. Cerebral MRI revealed an isolated lesion in the splenium of corpus callosum with slight hyperintense on T2 weighted images (T2WI), slight hypointense on T1 weighted images (T1WI), no enhancement on contrast images, obvious hyperintense on diffusion weighted imaging (DWI) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>), and decreased apparent diffusion coefficient (ADC) values (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Fractional anisotropy map revealed mildly decreased value of SCC lesion (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>), but with normally projecting direction of white matter fibers (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1f</xref>). At 4&#xA0;days after admission, the patient experienced several seizures again, and became deep comatose (GCS: 5). The patient was administrated with carbamazepine (400&#xA0;mg/d), methylprednisolone (1000&#xA0;mg/d), and intravenous immunoglobulin (IVIG) (2&#xA0;g/kg). The symptoms of seizure gradually disappeared, and the temperature returned to normal limits, while disturbance of consciousness was persistent. Laboratory examination revealed serum chemistry, blood routine, thyroid function, serum ammonia, tumor biomarkers, extractable nuclei antigen (ENA) polypeptide spectrum, and anti-neutrophil cytoplasmic antibody (ANCA) were normal. A lumbar puncture revealed a mild lymphocytic pleocytosis (20 cells/&#x3BC;L) with normal protein and glucose contents. Oligoclonal bands were negative in serum and CSF. The quantity of myelin basic protein (MBP) was 3.8ug/L (normal &lt;4ug/L) in CSF. Intrathecal IgG synthesis rate was 0.55&#xA0;mg/24&#xA0;h (normal &lt;0.7&#xA0;mg/24&#xA0;h). The etiological procedure found a positive PCR for influenza A in nasopharyngeal swabs, while other extensive microbiological workups were negative. At 17&#xA0;days after admission, second MRI showed the abnormalities of SCC nearly disappeared on DWI (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>) and ADC (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1e</xref>). Spinal cord MRI was normal. At 45&#xA0;days, he was transferred back to local hospital for nursing care. After 1&#xA0;year follow-up, the patient was in vegetative state, nasogastric tube feeding, and bedridden.<fig id="Fig1"><label>Fig. 1</label><caption><p>The cerebral MRI features of case 2. MRI revealed an isolated SCC lesion with obvious hyperintense on DWI (<bold>a</bold>, <italic>arrow</italic>), decreased ADC values (<bold>b</bold>), decreased fractional anisotropy value (<bold>c</bold>), and normally projecting direction of white matter fibers (<bold>f</bold>). At 16&#xA0;days after initial MRI, second MRI showed the abnormalities of SCC nearly disappeared on DWI (<bold>d</bold>) and ADC (<bold>e</bold>)</p></caption><graphic xlink:href="12883_2016_572_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Case 7</title>
        <p>A 16-year-old boy with the complaints of fever and headache for 5&#xA0;days, delirious behaviors for 3&#xA0;days, and consciousness disturbance for 1&#xA0;day was admitted to the hospital on February 12, 2014. The boy initially had fever, cough, and headache. After 3&#xA0;days, the patient presented with severe headache, vomiting, and irritability, so antiviral drug (acyclovir) was administrated. After 4&#xA0;days, he had consciousness disturbance, but no seizures were observed in the disease course. Physical examination on admission revealed comatose state (GCS: 8), slight limb movements responsive to pain stimulus, and negativity of bilateral pathological reflex. On admission, cerebral MRI showed an isolated lesion in the central SCC with slight hyperintense on T2WI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>), slight hypointense on T1WI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>), hyperintense on DWI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>), and apparent decreased ADC values (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>). A lumbar puncture revealed a mild elevation of cell counting (15 cells/uL) with normal protein and glucose content. Oligoclonal bands were negative in serum and CSF. The quantity of MBP was 3.3ug/L in CSF. Intrathecal IgG synthesis rate was 0.61&#xA0;mg/24&#xA0;h. Laboratory examination revealed serum chemistry, thyroid function, serum ammonia, tumor biomarkers, ENA polypeptide spectrum, and ANCA were normal. At 1&#xA0;day after admission, patients experienced more severe disturbance of consciousness, low blood pressure (70/50&#xA0;mmHg), and breathing difficulty with hypoxemia and acidosis, so mechanical ventilation was administrated immediately. Meanwhile, the patient was administrated with methylprednisolone (1000&#xA0;mg/d), IVIG (2&#xA0;g/kg), antiviral (acyclovir), and antibiotics (vancomycin). At 10&#xA0;days after admission, the patient had stable vital signs, while he was still in comatose state. At 32&#xA0;days after admission, second MRI showed abnormal signals of the SCC completely disappearing on T2WI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2e</xref>), T1WI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2f</xref>), DWI (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2g</xref>) and ADC (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2h</xref>). After 7&#xA0;months follow-up, the patient was in a condition of agrypnocoma, nasogastric tube feeding, and bedridden.<fig id="Fig2"><label>Fig. 2</label><caption><p>The cerebral MRI features of case 7. MRI showed an isolated SCC lesion with slight hyperintense on T2WI (<bold>a</bold>), slight hypointense on T1WI (<bold>b</bold>), hyperintense on DWI (<bold>c</bold>, <italic>arrow</italic>), and obvious decreased ADC values (<bold>d</bold>). At 32&#xA0;days after first MRI, second MRI showed abnormal signals of the SCC completely disappearing on T2WI (<bold>e</bold>), T1WI (<bold>f</bold>), DWI (<bold>g</bold>) and ADC (<bold>h</bold>)</p></caption><graphic xlink:href="12883_2016_572_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Result</title>
      <p>
        <list list-type="order">
          <list-item>
            <p>Clinical features</p>
            <p>Of the 23 patients with restricted diffusion on isolated lesion in SCC, 15 patients met the criteria for RESLES associated with encephalitis/encephalopathy and 8 patients were excluded from the study due to the following reasons: 6 had no follow-up MRI study; 1 had lesions in both SCC and bilateral white matters; 1 was associated with possible epilepsy-related RESLES due to withdrawal of antiepileptic agents. The clinical data and radiological images of 15 patients were reviewed by the co-authors together. The clinical findings of 15 patients were summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical data of patients with RESLES associated with encephalitis/encephalopathy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>patient no.</th><th>age/sex</th><th>initial symptom</th><th>CNS manifestation (onset day)</th><th>CNS diagnosis</th><th>EEG</th><th>CSF</th><th>pathogens</th><th>therapy</th><th>prognosis (day)</th></tr></thead><tbody><tr><td>1</td><td>15/M</td><td>fever</td><td>headache (2d)</td><td>encephalopathy</td><td>slow BA</td><td>normal</td><td>negative</td><td>None</td><td>CR (14d)</td></tr><tr><td>2</td><td>23/M</td><td>fever, nasal congestion, pharyngalgia</td><td>headache, seizure, disturbance of consciousness, meningeal irritation sign (6d)</td><td>meningoencephalitis</td><td>NE</td><td>CC: 20</td><td>influenza A</td><td>MPSL, IVIG, ACV, MV, CBZ, antibiotics,</td><td>vegetative state</td></tr><tr><td>3</td><td>27/F</td><td>fever, cough</td><td>headache, ataxia, slurred language (2d)</td><td>encephalopathy</td><td>NE</td><td>normal</td><td>negative</td><td>Dex, ACV</td><td>CR (9d)</td></tr><tr><td>4</td><td>38/M</td><td>fever, nasal congestion, cough</td><td>headache, vertigo (1d)</td><td>encephalopathy</td><td>NE</td><td>normal</td><td>herpesvirus-6</td><td>ACV</td><td>CR (11d)</td></tr><tr><td>5</td><td>26/M</td><td>fever, myalgias</td><td>headache, disturbance of consciousness (2d)</td><td>encephalitis</td><td>slow BA</td><td>CC:110</td><td>negative</td><td>ACV, Dex, antibiotics</td><td>CR (10d)</td></tr><tr><td>6</td><td>31/M</td><td>fever, pharyngalgia</td><td>vertigo (3d)</td><td>encephalopathy</td><td>slow BA</td><td>normal</td><td>negative</td><td>ACV, antibiotics</td><td>CR (20d)</td></tr><tr><td>7</td><td>16/M</td><td>fever, cough</td><td>headache, delirious behavior, disturbance of consciousness (2d)</td><td>encephalitis</td><td>NE</td><td>CC: 15</td><td>negative</td><td>MPSL, IVIG, ACV, MV,</td><td>agrypnocoma</td></tr><tr><td>8</td><td>37/F</td><td>fever, myalgias</td><td>headache, tremor (1d)</td><td>encephalopathy</td><td>normal</td><td>normal</td><td>negative</td><td>None</td><td>CR (25d)</td></tr><tr><td>9</td><td>25/F</td><td>fever, cough, pharyngalgia</td><td>headache, vertigo (3d)</td><td>encephalopathy</td><td>NE</td><td>normal</td><td>influenza B</td><td>ACV</td><td>CR(7d)</td></tr><tr><td>10</td><td>30/M</td><td>fever</td><td>limb numbness, slurred language (2d)</td><td>encephalopathy</td><td>normal</td><td>normal</td><td>negative</td><td>None</td><td>CR(12d)</td></tr><tr><td>11</td><td>30/F</td><td>fever, nasal congestion</td><td>headache, delirious behavior (5d)</td><td>encephalitis</td><td>normal</td><td>normal</td><td>EB virus</td><td>ACV, Dex</td><td>CR (7d)</td></tr><tr><td>12</td><td>13/M</td><td>fever</td><td>headache, disturbance of consciousness, seizure, meningeal irritation sign (1d)</td><td>meningoencephalolitis</td><td>slow BA</td><td>CC: 73</td><td>negative</td><td>ACV, PB, IVIG, antibiotics</td><td>CR (6d)</td></tr><tr><td>13</td><td>33/F</td><td>none</td><td>vertigo</td><td>encephalopathy</td><td>normal</td><td>normal</td><td>negative</td><td>None</td><td>CR (14d)</td></tr><tr><td>14</td><td>25/F</td><td>cough, pharyngalgia</td><td>headache (3d)</td><td>encephalopathy</td><td>NE</td><td>NE</td><td>negative</td><td>ACV</td><td>CR (10d)</td></tr><tr><td>15</td><td>15/M</td><td>fever</td><td>headache (1d)</td><td>encephalitis</td><td>normal</td><td>CC: 19</td><td>negative</td><td>ACV, Dex</td><td>CR (15d)</td></tr></tbody></table><table-wrap-foot><p>
<italic>CNS</italic> central nervous system, <italic>EEG</italic> electroencephalogram, <italic>CSF</italic> cerebrospinal fluid, <italic>BA</italic> basic activity, <italic>CR</italic> complete recovery, <italic>NE</italic> not examined, <italic>CC</italic> cell counting (cells/uL), <italic>MPSL</italic> methylprednisolone, <italic>IVIG</italic> intravenous immunoglobulin, <italic>ACV</italic> acyclovir, <italic>MV</italic> mechanical ventilation, <italic>CBZ</italic> carbamazepine, <italic>SL</italic> slurred language, <italic>Dex</italic> dexamethasone, <italic>PB</italic> phenobarbital</p></table-wrap-foot></table-wrap></p>
            <p>These patients included 9 males and 6 females, and their age at diagnostic time varied from 13 to 32&#xA0;years (average 25.6&#x2009;&#xB1;&#x2009;7.98). Fever preceded neurological symptoms in 13 patients. Eight patients initially had other cold symptoms before the onset of neurological symptoms. The cold symptoms included cough (5/8), pharyngalgia (4/8), nasal congestion (3/8), and myalgias (2/8). Viral pathogens were identified in 4 of 15 patients, including influenza A or B (positive PCR in nasopharyngeal swab), herpesvirus-6 (increased IgM antibody), and Epstein-Barr virus (positive PCR in CSF). The onset of neurological symptoms ranged from day 1 to 6 of the febrile illness. The most common neurological symptom is headache (12/15), followed by disturbance of consciousness (4/15), vertigo (4/15), seizure (2/15), delirious behavior (2/15), slurred language (2/15), ataxia (1/15), tremor (1/15), and limb numbness (1/15). Two patients were treated with mechanical ventilation. Two patients had received antiepileptic drugs (phenobarbital for case 2 and carbamazepine for case 12) after the time of MRI study. Analysis of CSF revealed pleocytosis in 5 of 14 examined patients but normal glucose and protein levels. EEG showed slow basic activity characteristic of encephalitis/encephalopathy in 4 of 9 examined patients. The therapeutic regimens were variable (e.g. acyclovir for 11 patients, corticosteroids for 6 patients, and IVIG administration for 3 patients), even 4 patients were not administrated purposeful treatments. Thirteen patients clinically recovered completely within 1&#xA0;month (9 patients within 2&#xA0;weeks after the onset of neurological symptoms) without any neurological sequelae, but 2 patients who were required mechanical ventilation had severe neurological sequelae.</p>
          </list-item>
          <list-item>
            <p>MRI characteristics</p>
            <p>In all of patients, the initial MRI study was performed within 1&#xA0;week of the onset of prodromal febrile illness (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). On axial images, the lesion was extended irregularly into the lateral portion of SCC in 2 patients (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) and ovoid in the center of the SCC in the other patients (case 1, 3, 4, 5, and 7&#x2013;15) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). There was no obvious correlation between the shape of SCC lesion and the scan date, neurological symptoms (presence or absence of seizures, date of complete recovery, with or without sequelea), or laboratory findings. The initial MRI features showed homogeneously restricted diffusion with hyperintense on DWI and decreased ADC values in SCC lesions. The lesions of SCC were homogeneously slight hyperintense on T2WI, while the lesions can be isointense to slight hypointense on T1WI. There was no enhancement of the SCC lesion after gadolinium administration in any of the 7 patients who received enhanced MRI. The SCC abnormalities of all 15 patients disappeared at follow-up MRI studies performed 10 to 32&#xA0;days after the first MRI study. In at least 4 patients (case 1, 2, 7, 10), the SCC lesions disappeared before clinical symptoms reached stability or complete recovery.<table-wrap id="Tab2"><label>Table 2</label><caption><p>MRI characteristics of RESLES associated with encephalitis/encephalopathy</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">patient no.</th><th colspan="9">initial MRI</th><th colspan="2">follow-up MRI</th></tr><tr><th>scan date<sup>1</sup>
</th><th>lesion</th><th>shape</th><th>T2WI</th><th>T1WI</th><th>Gd</th><th>DWI</th><th>ADC</th><th>DTI</th><th>scan date<sup>2</sup>
</th><th>scan date<sup>2</sup>
</th></tr></thead><tbody><tr><td>1</td><td>day 5</td><td>SCC</td><td>ovoid</td><td>H</td><td>sL</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 12</td><td>none</td></tr><tr><td>2</td><td>day 7</td><td>SCC</td><td>extended</td><td>sH</td><td>sL</td><td>none</td><td>H</td><td>L</td><td>L</td><td>day 16</td><td>none</td></tr><tr><td>3</td><td>day 4</td><td>SCC</td><td>ovoid</td><td>H</td><td>L</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 10</td><td>none</td></tr><tr><td>4</td><td>day 5</td><td>SCC</td><td>ovoid</td><td>sH</td><td>I</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 12</td><td>none</td></tr><tr><td>5</td><td>day 3</td><td>SCC</td><td>ovoid</td><td>H</td><td>sL</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 11</td><td>none</td></tr><tr><td>6</td><td>day 4</td><td>SCC</td><td>ovoid</td><td>sH</td><td>I</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 28</td><td>none</td></tr><tr><td>7</td><td>day 5</td><td>SCC</td><td>ovoid</td><td>sH</td><td>sL</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 32</td><td>none</td></tr><tr><td>8</td><td>day 2</td><td>SCC</td><td>ovoid</td><td>sH</td><td>I</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 27</td><td>none</td></tr><tr><td>9</td><td>day 3</td><td>SCC</td><td>ovoid</td><td>H</td><td>L</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 14</td><td>none</td></tr><tr><td>10</td><td>day 3</td><td>SCC</td><td>extended</td><td>sH</td><td>sL</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 10</td><td>none</td></tr><tr><td>11</td><td>day 5</td><td>SCC</td><td>ovoid</td><td>sH</td><td>I</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 25</td><td>none</td></tr><tr><td>12</td><td>day 6</td><td>SCC</td><td>ovoid</td><td>sH</td><td>sL</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 15</td><td>none</td></tr><tr><td>13</td><td>day 1</td><td>SCC</td><td>ovoid</td><td>sH</td><td>I</td><td>NE</td><td>H</td><td>L</td><td>NE</td><td>day 17</td><td>none</td></tr><tr><td>14</td><td>day 4</td><td>SCC</td><td>ovoid</td><td>sH</td><td>sL</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 14</td><td>none</td></tr><tr><td>15</td><td>day 3</td><td>SCC</td><td>ovoid</td><td>H</td><td>L</td><td>none</td><td>H</td><td>L</td><td>NE</td><td>day 16</td><td>none</td></tr></tbody></table><table-wrap-foot><p>
<italic>scan date</italic>
<sup><italic>1</italic></sup> from the initial symptoms, <italic>scan date</italic>
<sup><italic>2</italic></sup>from the initial MRI. <italic>T2W</italic> T2-weighted image, <italic>T1WI</italic> T1-weighted image, <italic>Gd</italic> gadolinium enhancement, <italic>DWI</italic> diffusion weighted imaging, <italic>ADC</italic> apparent diffusion coefficient, <italic>DTI</italic> diffusion tensor imaging, <italic>SCC</italic> splenium of the corpus callosum, <italic>H</italic> high intensity, <italic>L</italic> low intensity, <italic>I</italic> isointensity, <italic>sH</italic> slight high intensity, <italic>sL</italic> slight low intensity, <italic>NE</italic> not examined</p></table-wrap-foot></table-wrap></p>
          </list-item>
        </list>
      </p>
    </sec>
    <sec id="Sec6">
      <title>Discussion</title>
      <p>In this study, we described the clinical characteristics and outcomes in 15 patients with RESLES associated with encephalitis/encephalopathy in mainland China. These patients initially presented with febrile illness, and then had CNS manifestations after several days. Due to the limits of pathogens and CSF examinations, 6 patients can be considered as encephalitis, while 9 other patients can be only diagnosed as infection-associated encephalopathy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, all patients had a complete radiological regression of the isolated SCC lesion within several weeks.</p>
      <p>Almost all patients with RESLES could be complete recovery without neurological sequelae after the acute disease course [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, RESLES associated with encephalitis/encephalopathy was also known as a type of clinically mild encephalitis/encephalopathy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, we found two patients (case 2 and 7), who required ventilator supporting in the acute period of disease course, had persistent comatose state and poor prognosis, even though the abnormal lesions disappeared within 1&#xA0;month. Through detailed clinical investigations, the typical evidences of acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), autoimmune encephalitis, vasculitis of central nervous system, and various metabolic or toxic encephalopathies were not found in the two patients. Although some rare underlying disorders can not be completely excluded, the clinical pictures of the two patients conformed to the diagnosis of RESLES associated with encephalitis/encephalopathy. Therefore, RESLES associated with encephalitis/encephalopathy should not be simply considered as a mild clinic-radiological disorder with an excellent prognosis, particularly in patients required ventilator supporting in acute stage of disease course.</p>
      <p>Due to the insufficient number of patients, there had been no evidence-based therapeutic regimen for RESLES associated with encephalitis/encephalopathy. According to the descriptions of literatures, the commonest prescriptions included acyclovir, antibiotics, anti-epileptic drugs, corticosteroids, and IVIG [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. We also found that the treatment can change from one case to other case in our observational patients; even 4 cases with good prognosis had not been administrated any purposeful treatments.</p>
      <p>The pathogenesis of the selective splenial lesion is not fully understood in RESLES associated with encephalitis/encephalopathy. Multiple etiologies are considered involvements into the splenial lesion [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Therefore, as a distinct radiological spectrum disorder, cerebral MRI still is the first choice to identify lesions of the SCC, particularly to detect early changes, and helps interpret the nature of the lesion [<xref ref-type="bibr" rid="CR1">1</xref>]. The SCC lesions consistently showed a homogeneous and reversible pattern on DWI, differentiating these lesions from persistent ischemia, where ADC reduction with subsequent reversal is uncommon. Our cases showed reversible DWI and ADC reduction supporting that cytotoxic edema of the SCC is an important mechanism in this condition. Interestedly, we found the SCC lesion presented with decreased fractional anisotropy values in the initial MRI scanning, which was different from the findings described by other cases [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The decreased fractional anisotropy values in areas of diffusion restriction may indicate the disarrangement of water molecule motivation along the axonal fibers, which also may indicate the destruction of bridge architecture associated with neurological deficits in the patient. However, the clinical significance between fractional anisotropy value and prognosis should be further investigated in more cases. In addition, some cases with slightly tinny hyperintense on T2 and DWI had severe clinical course and poor outcomes, but other cases with obvious hyperintense on T2 and DWI presented with slight clinical course. The phenomenon might indicate that the intensity and formation of SCC lesion were not closely associated with the clinical features.</p>
      <p>Since a few patients with ADEM can present with isolated SCC lesion in early stage of disease course [<xref ref-type="bibr" rid="CR22">22</xref>], ADEM should be a differential diagnosis of RESLES associated with encephalitis/encephalopathy. ADEM is an immune inflammatory disorder, which is clinically characterized as seizures, focal neurological signs, disturbance of consciousness, and recovery after immunomodulatory therapy. MRI in ADEM usually shows multiple foci of T1 and T2 prolongation with enhancement in bilateral or asymmetric subcortical white matters [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, we excluded a case with lesions both SCC and bilateral white matters in order to obtain a more strict clinical diagnosis, although some patients with RESLES associated with encephalitis/encephalopathy were well described with additional white matter lesions [<xref ref-type="bibr" rid="CR23">23</xref>]. The lesions of ADEM usually evolve over weeks to months and disappear only after several months [<xref ref-type="bibr" rid="CR21">21</xref>]. However, our patients developed neurological symptoms quickly after the onset of febrile illness. The SCC lesions in these patients had no contrast enhancement, and most of them disappeared completely within month. Therefore, the SCC lesions in our patients are clinically and radiologically different from those of ADEM. Autoimmune encephalitis such as anti-N-methyl-D-aspartate (NMDA) receptor encephalitis also should be differentiated [<xref ref-type="bibr" rid="CR24">24</xref>]. Corpus callosum can be affected in very few patients with anti-NMDA receptor encephalitis, while the lesions were not quickly reversible diffusion restriction with reduced apparent diffusion coefficient in patients who usually were young female with ovarian teratoma [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
      <p>The major limitations of our work were its retrospective nature and relatively small sample size. A larger prospective study with long-term follow-up would be necessary to corroborate our findings.</p>
    </sec>
    <sec id="Sec7">
      <title>Conclusion</title>
      <p>RESLES associated with encephalitis/encephalopathy is a distinct disorder, which usually affects children or young adults with febrile illness. Although RESLES associated with encephalitis/encephalopathy is a reversible syndrome with an excellent prognosis in most patients, a few patients required ventilator supporting at the early stage might have severe neurological sequelae. Reversible signal changes on DWI and ADC are identified in all of patients, but fractional anisotropy values can be decreased in severe patient with neurological sequelae.</p>
      <sec id="Sec8">
        <title>Ethics and consent to participate</title>
        <p>This study was approved by the ethics committee of the First Affiliated Hospital of Nanchang University.</p>
      </sec>
      <sec id="Sec9">
        <title>Consent to publish</title>
        <p>Written consent for publication had obtained from patients or their parents.</p>
      </sec>
      <sec id="Sec10" sec-type="materials|methods">
        <title>Availability of data and materials</title>
        <p>The detailed descriptions about those patients can be available in a Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec32">
          <title>Additional file</title>
          <p>
            <media position="anchor" xlink:href="12883_2016_572_MOESM1_ESM.doc" id="MOESM1">
              <label>Additional file 1:</label>
              <caption>
                <p>Reversible splenial lesion syndrome associated with encephalitis/encephalopathy presenting with great clinical heterogeneity. (52 kb)</p>
              </caption>
            </media>
          </p>
        </sec>
      </app>
    </app-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>RESLES</term>
          <def>
            <p>Reversible splenial lesion syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>SCC</term>
          <def>
            <p>splenium of the corpus callosum</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>magnetic resonance image</p>
          </def>
        </def-item>
        <def-item>
          <term>EEG</term>
          <def>
            <p>electroencephalogram</p>
          </def>
        </def-item>
        <def-item>
          <term>CSF</term>
          <def>
            <p>cerebrospinal fluid</p>
          </def>
        </def-item>
        <def-item>
          <term>PCR</term>
          <def>
            <p>polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>T2WI</term>
          <def>
            <p>T2 weighted images</p>
          </def>
        </def-item>
        <def-item>
          <term>T1WI</term>
          <def>
            <p>T1 weighted images</p>
          </def>
        </def-item>
        <def-item>
          <term>DWI</term>
          <def>
            <p>diffusion wighted imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>ADC</term>
          <def>
            <p>apparent diffusion coefficient</p>
          </def>
        </def-item>
        <def-item>
          <term>IVIG</term>
          <def>
            <p>intravenous immunoglobulin</p>
          </def>
        </def-item>
        <def-item>
          <term>ENA</term>
          <def>
            <p>extractable nucler antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>ANCA</term>
          <def>
            <p>anti-neutrophil cytoplasmic antibody</p>
          </def>
        </def-item>
        <def-item>
          <term>MBP</term>
          <def>
            <p>myelin basic protein</p>
          </def>
        </def-item>
        <def-item>
          <term>ADEM</term>
          <def>
            <p>acute disseminated encephalomyelitis</p>
          </def>
        </def-item>
        <def-item>
          <term>MS</term>
          <def>
            <p>multiple sclerosis</p>
          </def>
        </def-item>
        <def-item>
          <term>NMDA</term>
          <def>
            <p>N-methyl-D-aspartate</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>ZY data collection and manuscript composition; ZJ clinical follow-up and helped data analysis; ZL drafted the manuscript and gave critical suggestions; ZZ intensive cure for the two severe patients and helped data analysis; ZM radiological data analysis; LX contributed a patient and gave critical suggestions; LX and WH neurological evaluation of the patient and critical suggestions for manuscript composition; HD design the study, manuscript composition, and corresponding author. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We appreciated patients and their families for their cooperation. We also thank Ms. Andrews Vidita helping us polish language.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>The design of study and collection work was funded by the National Natural Science Foundation of China (No.81260194 and 81460199).</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kashiwagi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanabe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimakawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shabana</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinico-radiological spectrum of reversible splenial lesions in children</article-title>
          <source>Brain Dev.</source>
          <year>2014</year>
          <volume>36</volume>
          <fpage>330</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2013.05.007</pub-id>
          <pub-id pub-id-type="pmid">23790266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takanashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barkovich</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Oba</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsukahara</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinically mild encephalitis/encephalopathy with a reversible splenial lesion</article-title>
          <source>Neurology.</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>1854</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1212/01.WNL.0000144274.12174.CB</pub-id>
          <pub-id pub-id-type="pmid">15557501</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polster</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ebner</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Transient lesion in the splenium of the corpus callosum: three further cases in epileptic patients and a pathophysiological hypothesis</article-title>
          <source>J Neurol Neurosurg Psychiatry.</source>
          <year>2001</year>
          <volume>70</volume>
          <fpage>459</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1136/jnnp.70.4.459</pub-id>
          <pub-id pub-id-type="pmid">11254767</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirsattari</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Blume</surname>
              <given-names>WT</given-names>
            </name>
          </person-group>
          <article-title>Transient lesion in the splenium of the corpus callosum in an epileptic patient</article-title>
          <source>Neurology.</source>
          <year>2003</year>
          <volume>60</volume>
          <fpage>1838</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1212/01.WNL.0000058754.99940.11</pub-id>
          <pub-id pub-id-type="pmid">12796545</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganapathy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ey</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Wolfson</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Transient isolated lesion of the splenium associated with clinically mild influenza encephalitis</article-title>
          <source>Pediatr Radiol.</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>1243</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1007/s00247-008-0949-z</pub-id>
          <pub-id pub-id-type="pmid">18668232</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchigami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A 4-year-old girl with clinically mild encephalopathy with a reversible splenial lesion associated with rotavirus infection</article-title>
          <source>J Infect Chemother.</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>149</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1007/s10156-012-0421-8</pub-id>
          <pub-id pub-id-type="pmid">22569794</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mizuochi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shibuya</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ohya</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination</article-title>
          <source>Brain Dev.</source>
          <year>2011</year>
          <volume>33</volume>
          <fpage>842</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2010.12.013</pub-id>
          <pub-id pub-id-type="pmid">21273018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with febrile urinary tract infection</article-title>
          <source>Eur J Pediatr.</source>
          <year>2014</year>
          <volume>173</volume>
          <fpage>533</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-013-2199-9</pub-id>
          <pub-id pub-id-type="pmid">24221606</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lype</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ahamed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kailas</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Acute encephalopathy with a lesion of the splenium of the corpus callosum--a report of two cases</article-title>
          <source>Brain Dev.</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>322</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2011.06.004</pub-id>
          <pub-id pub-id-type="pmid">21723059</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takanashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayakawa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Terada</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</article-title>
          <source>J Neurol Sci.</source>
          <year>2010</year>
          <volume>292</volume>
          <fpage>24</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jns.2010.02.013</pub-id>
          <pub-id pub-id-type="pmid">20236662</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Britton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Troedson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Procopis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ging</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mild encephalopathy with reversible splenial lesion: an important differential of encephalitis</article-title>
          <source>Eur J Paediatr Neurol.</source>
          <year>2015</year>
          <volume>19</volume>
          <fpage>377</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpn.2015.01.011</pub-id>
          <pub-id pub-id-type="pmid">25707871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Degirmenci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Degirmenci</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cetin</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>K&#x131;ro&#x11F;lu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) in a patient presenting with papilledema</article-title>
          <source>Acta Neurol Belg.</source>
          <year>2015</year>
          <volume>115</volume>
          <fpage>153</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1007/s13760-014-0314-y</pub-id>
          <pub-id pub-id-type="pmid">24895074</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Monco</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Cortina</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cabrera</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reversible splenial lesion syndrome (RESLES): what&#x2019;s in a name?</article-title>
          <source>J Neuroimaging.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>e1</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1552-6569.2008.00279.x</pub-id>
          <pub-id pub-id-type="pmid">18681931</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takanashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaiho</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ota</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A splenial lesion with transiently reduced diffusion in clinically mild encephalitis is not always reversible: A case report</article-title>
          <source>Brain Dev.</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>710</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2008.10.005</pub-id>
          <pub-id pub-id-type="pmid">19046838</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoshino</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saitoh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes</article-title>
          <source>Brain Dev.</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>337</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2011.07.012</pub-id>
          <pub-id pub-id-type="pmid">21924570</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venkatesan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tunkel</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Bloch</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Lauring</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Sejvar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bitnun</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium</article-title>
          <source>Clin Infect Dis.</source>
          <year>2013</year>
          <volume>57</volume>
          <fpage>1114</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/cit458</pub-id>
          <pub-id pub-id-type="pmid">23861361</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fluss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Menache-Starobinski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Delavelle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Van Bogaert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Mild influenza-associated encephalopathy/encephalitis with a reversible splenial lesion in a Caucasian child with additional cerebellar features</article-title>
          <source>Eur J Paediatr Neurol.</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>97</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpn.2009.09.007</pub-id>
          <pub-id pub-id-type="pmid">19819739</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ushiroda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakatomi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Motomura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Moriuchi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Kawasaki disease-associated MERS: pathological insights from SPECT findings</article-title>
          <source>Brain Dev.</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>605</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2011.09.015</pub-id>
          <pub-id pub-id-type="pmid">22019463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tanuma</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takanashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</article-title>
          <source>Brain Dev.</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>124</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2011.04.004</pub-id>
          <pub-id pub-id-type="pmid">21576007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osuka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Matsushita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nozue</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mild encephalitis/encephalopathy with a reversible splenial lesion: evaluation by diffusion tensor imaging. Two case reports</article-title>
          <source>Neurol Med Chir (Tokyo)</source>
          <year>2010</year>
          <volume>50</volume>
          <fpage>1118</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.2176/nmc.50.1118</pub-id>
          <pub-id pub-id-type="pmid">21206192</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Shankar B, Narayanan R, Muralitharan P, Ulaganathan B. Evaluation of mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) by diffusion-weighted and diffusion tensor imaging. BMJ Case Rep. 2014;2014:bcr2014204078.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fridinger</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Alper</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Defining encephalopathy in acute disseminated encephalomyelitis</article-title>
          <source>J Child Neurol</source>
          <year>2013</year>
          <volume>87</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cho</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mild encephalopathy with reversible lesion in the splenium of the corpus callosum and bilateral frontal white matter</article-title>
          <source>J Clin Neurol.</source>
          <year>2007</year>
          <volume>3</volume>
          <fpage>53</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.3988/jcn.2007.3.1.53</pub-id>
          <pub-id pub-id-type="pmid">19513344</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dubey</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sawhney</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lowden</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Warnack</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Khemani</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The spectrum of autoimmune encephalopathies</article-title>
          <source>J Neuroimmunol.</source>
          <year>2015</year>
          <volume>287</volume>
          <fpage>93</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jneuroim.2015.08.014</pub-id>
          <pub-id pub-id-type="pmid">26439968</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Anti-NMDAR autoimmune encephalitis</article-title>
          <source>Brain Dev.</source>
          <year>2014</year>
          <volume>36</volume>
          <fpage>645</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2013.10.005</pub-id>
          <pub-id pub-id-type="pmid">24211006</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
